Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) resulting...
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apimeds Pharmaceuticals US, Inc. (NYSE American:...
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. (“Inscobee”) and Apimeds, Inc., (“Apimeds Korea”) today announced...
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. (“Inscobee”) and Apimeds, Inc., (“Apimeds Korea”) today announced...
MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March...
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP)...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds’ late-stage, non-opioid pain-management biologic portfolio with MindWave’s AI-driven...
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College...
Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai ² Futures Lab program through a new collaboration...